FDA Clearance Tracker · P230036
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 26, 2024
Approved
Time to decision
178 days
Received Oct 31, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P230036
- Device name
- Esprit BTK Everolimus Eluting Resorbable Scaffold System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Santa Clara, CA
- Received
- Oct 31, 2023
- Decided
- Apr 26, 2024
- Decision
- Approved
- Supplements
- 19 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Scaffold, infrapopliteal, absorbable (NXW)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
The Esprit BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with Chronic Limb Threatening Ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of >= 2.5 mm and <= 4.00 mm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code NXW (Scaffold, infrapopliteal, absorbable).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.